In our previous study of CSF metabolites, we found an association between higher CSF levels of shikimate and IDH-wildtype gliomas compared to controls [2], a finding recapitulated in Fig. 3C. CSF shikimate levels have also been found to be elevated in patients with autism spectrum disorder [5]. Here, IDH1 is linked to glioma.